Syros is dedicated to developing therapies that control gene expression with the aim of providing a profound and durable benefit for patients.
Our lead program, tamibarotene, an oral, selective retinoic acid receptor alpha agonist, is currently being evaluated in a pivotal Phase 3 trial in a genomically defined subset of patients with myelodysplastic syndrome for which pivotal data are expected by mid-Q4 2024, and in a randomized Phase 2 trial in a genomically defined subset of patients with AML for which encouraging data were reported in December 2023. We hold exclusive development and commercial rights to tamibarotene for cancer indications in the Americas, Europe, Australia and Israel. We are exploring partnership opportunities to develop and commercialize tamibarotene in the territories outside the United States.
Additionally, we have worldwide rights for SY-5609, an oral reversible inhibitor of CDK7 with best-in-class selectivity and potency, and we are seeking global out-license opportunities for further development.
Contact us at firstname.lastname@example.org to learn more about partnership opportunities.